Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309713915> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4309713915 endingPage "284" @default.
- W4309713915 startingPage "280" @default.
- W4309713915 abstract "Background To examine safety and efficacy of tezacaftor-ivacaftor (TEZ/IVA) in a real-life setting in adults living with cystic fibrosis.Methods A multicentre retrospective observational study, including adults living with cystic fibrosis (pwCF) eligible for TEZ/IVA, with assessments at baseline, 3 months (visit3mo) and 6 months (visit6mo) after start of treatment. Outcomes included change in FEV1, LCI, FeNO, CFQ-R, estimated number of annual acute exacerbations, BMI, dosage of pancreatic enzyme replacement therapy (PERT) and airway microbiology. We also assessed safety.Results Forty-eight adult pwCF (mean (±SD) age 33 (±12) years; mean FEV1 65 (±19) %P) were included. Three subgroups were identified: pwCF F/F CFTR modulator-naive (n = 28; 58%), pwCF F/F previously treated with lumacaftor-ivacaftor (n = 11; 23%) and pwCF F/RF (n = 9; 19%). Adverse events were described in 3 pwCF (6%) during the 6-month observation period (in one leading to treatment interruption). At visit3mo, FEV1 had improved in all subgroups. In the entire group, mean FEV1 had increased from 66 (±2.9) %P to 72 (±2.9) %P (p < 0.0001). Similarly, LCI improved by approximately one unit at visit3mo (p = 0.02). At visit6mo mean annual acute exacerbation rate decreased significantly (p = 0.02). Only in the CFQ-R social functioning domain score, a significant improvement was observed at visit6mo (p < 0.01).Conclusions We showed that TEZ/IVA is safe, well tolerated and effective in terms of improvement of lung function, ventilation inhomogeneity, health-related social functioning, and reduction of estimated annual acute exacerbation rate, in adult pwCF F/F and F/RF. Results in this real-life study reflect those observed in RCTs." @default.
- W4309713915 created "2022-11-29" @default.
- W4309713915 creator A5001772456 @default.
- W4309713915 creator A5021489999 @default.
- W4309713915 creator A5034739519 @default.
- W4309713915 creator A5041529205 @default.
- W4309713915 creator A5069785766 @default.
- W4309713915 creator A5080878747 @default.
- W4309713915 date "2022-11-22" @default.
- W4309713915 modified "2023-09-26" @default.
- W4309713915 title "Real-world data on the efficacy and safety of tezacaftor-ivacaftor in adults living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation" @default.
- W4309713915 cites W2051836609 @default.
- W4309713915 cites W2589766919 @default.
- W4309713915 cites W2765825922 @default.
- W4309713915 cites W2967773961 @default.
- W4309713915 cites W2979464486 @default.
- W4309713915 cites W3117110929 @default.
- W4309713915 cites W3120451132 @default.
- W4309713915 cites W3128973022 @default.
- W4309713915 cites W4206217612 @default.
- W4309713915 cites W4225754820 @default.
- W4309713915 doi "https://doi.org/10.1080/17843286.2022.2145684" @default.
- W4309713915 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36415912" @default.
- W4309713915 hasPublicationYear "2022" @default.
- W4309713915 type Work @default.
- W4309713915 citedByCount "0" @default.
- W4309713915 crossrefType "journal-article" @default.
- W4309713915 hasAuthorship W4309713915A5001772456 @default.
- W4309713915 hasAuthorship W4309713915A5021489999 @default.
- W4309713915 hasAuthorship W4309713915A5034739519 @default.
- W4309713915 hasAuthorship W4309713915A5041529205 @default.
- W4309713915 hasAuthorship W4309713915A5069785766 @default.
- W4309713915 hasAuthorship W4309713915A5080878747 @default.
- W4309713915 hasConcept C126322002 @default.
- W4309713915 hasConcept C197934379 @default.
- W4309713915 hasConcept C23131810 @default.
- W4309713915 hasConcept C2776502428 @default.
- W4309713915 hasConcept C2776938444 @default.
- W4309713915 hasConcept C2777014857 @default.
- W4309713915 hasConcept C2778428886 @default.
- W4309713915 hasConcept C71924100 @default.
- W4309713915 hasConcept C90924648 @default.
- W4309713915 hasConceptScore W4309713915C126322002 @default.
- W4309713915 hasConceptScore W4309713915C197934379 @default.
- W4309713915 hasConceptScore W4309713915C23131810 @default.
- W4309713915 hasConceptScore W4309713915C2776502428 @default.
- W4309713915 hasConceptScore W4309713915C2776938444 @default.
- W4309713915 hasConceptScore W4309713915C2777014857 @default.
- W4309713915 hasConceptScore W4309713915C2778428886 @default.
- W4309713915 hasConceptScore W4309713915C71924100 @default.
- W4309713915 hasConceptScore W4309713915C90924648 @default.
- W4309713915 hasIssue "4" @default.
- W4309713915 hasLocation W43097139151 @default.
- W4309713915 hasLocation W43097139152 @default.
- W4309713915 hasOpenAccess W4309713915 @default.
- W4309713915 hasPrimaryLocation W43097139151 @default.
- W4309713915 hasRelatedWork W1978933512 @default.
- W4309713915 hasRelatedWork W2596109810 @default.
- W4309713915 hasRelatedWork W2598098419 @default.
- W4309713915 hasRelatedWork W2918191288 @default.
- W4309713915 hasRelatedWork W4224260182 @default.
- W4309713915 hasRelatedWork W4281621095 @default.
- W4309713915 hasRelatedWork W4308223774 @default.
- W4309713915 hasRelatedWork W4362453769 @default.
- W4309713915 hasRelatedWork W4379980761 @default.
- W4309713915 hasRelatedWork W80541691 @default.
- W4309713915 hasVolume "78" @default.
- W4309713915 isParatext "false" @default.
- W4309713915 isRetracted "false" @default.
- W4309713915 workType "article" @default.